01 December 2023
01 December 2023
Changing trends show a reduction in HCP contact with the pharma industry and an increased prioritisation of in-person contact.
Despite violations at 15 out of 39 sites involved in the study, BioVie reported positive data from its trial investigating NE3107.
In the trial, tested doses of CYB003 demonstrated to have a favourable safety and tolerability profile.
Experts at the clinical conference continued to explore ways to improve representation in clinical trials and the regulatory push behind it.
Following the approval of NiCord earlier this year, there are more candidates coming to late-stage trials looking to target GvHD.
Change from baseline to week 12 on the HQ-CT score is the study’s primary efficacy endpoint.
The company plans to administer the dose to a third patient early next year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
